Real-life Assessment of the Safety and Performance of the SYNOVIUM HCS Device

Last updated: October 13, 2023
Sponsor: LCA Pharmaceutical
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Intra-articular injection of hyaluronic acid

Clinical Study ID

NCT06087705
YNOVIUM
  • Ages 18-90
  • All Genders

Study Summary

Patients who are to benefit from an injection of SYNOVIUM HCS as part of their care will be offered to participate in this study. Patients will need to sign a consent form to participate. Prior to SYNOVIUM HCS injection, patients will be asked a series of questions regarding their pain and disability. Data collected during follow-up visits can be compared to pre-injection data.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult patient
  • Patient with radiologically characterized gonarthrosis (stages Kellgren & Lawrencegrades I to III)
  • Patient with walking pain (WOMAC A1) at least equal to 2 on the Likert scale 0-4
  • Patient to benefit from an injection of SYNOVIUM HCS as part of his treatment
  • Patient agreeing to participate in the study
  • Patient affiliated to a social security scheme or benefiting from such a scheme

Exclusion

Exclusion Criteria:

  • Viscosupplementation less than 6 months old
  • Intra-articular corticosteroid injection less than 2 months old
  • Inflammatory arthritis or active infectious of the knee studied
  • History of surgery of the lower limb concerned
  • Kellgren & Lawrence grades not defined
  • Known hypersensitivity to hyaluronic acid or chondroitin sulfate
  • Pregnant or breastfeeding women
  • Patient under guardianship, curatorship or judicial safeguard
  • Patient participating in another clinical investigation, at the time of inclusion

Study Design

Total Participants: 134
Treatment Group(s): 1
Primary Treatment: Intra-articular injection of hyaluronic acid
Phase:
Study Start date:
February 07, 2023
Estimated Completion Date:
August 01, 2024

Study Description

Inclusion period: 6 months

Follow-up period:

  • 6-month follow-up, after intra-articular injection with extension

    • 1 single syringe of SYNOVIUM HCS (3 mL),

    • Controls scheduled at 1 week, 1, 3, 6 months and up to 1 year

    • Additional control (single) in the event of leaving the study if this takes place outside the scheduled visit dates and before 1 year, for medical reasons

  • Duration of the study: Overall time estimated at 18 months

  • In this open-label CI, the group itself is used as a control, by comparing the scores on inclusion with those of the various control visits.

Connect with a study center

  • CRRF en Milieu Marin de Trestel

    Saint-Brieuc, 22000
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.